Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The primary objective of this study is to evaluate the effect of KRN23 (burosumab) therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).
Epistemonikos ID: c8ba74ec62226f9484e7c61fd061de20814eb565
First added on: May 17, 2024